All articles by GlobalData Healthcare

  1. Gilead led the global infectious diseases space in 2017

    GlobalData projects the total revenue from branded infectious diseases (ID) drugs and vaccines to surpass $75bn in 2017. Bolstered by…
    Read More…

    22 Feb
  2. AAD 2018: strong Phase IIb results for upadacitinib in atopic dermatitis

    On 17 February, primary results from a Phase IIb clinical trial assessing the use of AbbVie’s upadacitinib in adult patients…
    Read More…

    22 Feb
  3. Will Amazon be the new face of healthcare?

    The US healthcare system is an expensive and outdated giant. It is the world’s most expensive and only for-profit healthcare…
    Read More…

    22 Feb
  4. The ophthalmology biosimilars market is still in its infancy

    2017 has proved to be a remarkable year for biosimilars in ophthalmology, with the EMA approval of Amgen’s Amgevita in…
    Read More…

    21 Feb
  5. AAD 2018: Is Tremfya more cost-effective than Cosentyx and Taltz?

    At the 76th annual meeting of the American Academy of Dermatology, Johnson & Johnson (J&J) released a cost per responder…
    Read More…

    21 Feb
  6. Biogen continues to dominate the neurology market

    Among the top 10 players in neurology, Biogen is the only company that generated more than 50% of its total…
    Read More…

    21 Feb
  7. AAD 2018: AbbVie’s risankizumab boasts strong Phase III data in psoriasis

    On February 17th, Phase III head to head clinical trial data assessing the use of AbbVie’s risankizumab in comparison with…
    Read More…

    21 Feb
  8. Small pharma steals the spotlight in 2017 antibiotics space

    In November 2017, Melinta Therapeutics acquired The Medicine Company’s infectious diseases business unit as part of a $270M agreement, capping…
    Read More…

    20 Feb
  9. Biosimilars: past and future deals

    Biosimilars are becoming increasingly popular with pharmaceutical companies; however, knowing which markets have been saturated with biosimilars and which are…
    Read More…

    19 Feb
  10. Anticoagulants drive market growth in multiple cardiovascular disease

    Major growth in the anticoagulant market continued through 2017, primarily due to the increasing global prevalence of multiple cardiovascular (CV)…
    Read More…

    16 Feb